The GI-MAP™ has expanded to include five new bacterial biomarkers.
The additions include keystone species and important groups that may impact health in a variety of ways, including: production of short-chain fatty acids, mucus metabolism, methane production, and promotion of anti-inflammatory regulatory T cells, and production of inflammatory LPS.
These markers will further enhance insights into gastrointestinal and immune health provided by GI-MAP DNA Stool Analysis.
New Commensal Biomarkers
- Akkermansia mucinophila: Plays a significant role in the gut ecosystem by breaking down mucus polysaccharides. Low levels are associated with obesity and metabolic dysfunction, while high levels are linked to multiple sclerosis.
- Clostridia (class*): Important producers of short-chain fatty acids, and have many well-documented roles in promoting a healthy intestinal barrier, immune balance, and protection against pathogens.
- Faecalbacterium prausnitzii: A well-known keystone, butyrate-producing species. Many chronic inflammatory and autoimmune diseases have been associated with low levels of F. prausnitzii.
New Opportunistic Biomarkers
- Methanobacteriaceae (family): Family of bacteria-like microbes that produce methane. High levels have been linked to chronic constipation, as well as some types of SIBO and IBS.
- Fusobacterium spp.: Commonly found in the oral cavity and may also be found in the intestine. Some are considered opportunistic pathogens, and may promote inflammatory processes and or advanced disease states.